title: Vorinostat-induced bone loss might be related to drug toxicity.
authors.affiliation: Department of Lung Cancer Surgery, Lung Cancer Institute, Tianjin Medical University General Hospital, Tianjin, PR China; Stem Cell Laboratory-Division Clinical Hematology, Universitair Ziekenhuis Brussel (UZ Brussel), Brussels, Belgium; Department of Hematology and Immunology, Vrije Universiteit Brussel (VUB), Myeloma Center Brussels, Brussels, Belgium.
authors.forename: Song
authors.initials: S
authors.lastname: Xu
authors.forename: Kim
authors.initials: K
authors.lastname: De Veirman
authors.forename: Karin
authors.initials: K
authors.lastname: Vanderkerken
authors.forename: Ivan
authors.initials: I
authors.lastname: Van Riet
mesh_terms: D000818:Animals; D001862:Bone Resorption / Q000139:chemically induced*; D004334:Drug Administration Schedule; D005786:Gene Expression Regulation / Q000187:drug effects; D056572:Histone Deacetylase Inhibitors / Q000009:adverse effects; D006801:Humans; D006877:Hydroxamic Acids / Q000008:administration & dosage / Q000009:adverse effects*; D020128:Inhibitory Concentration 50; D059630:Mesenchymal Stem Cells / Q000166:cytology; D051379:Mice; D010012:Osteogenesis / Q000187:drug effects / Q000235:genetics; D000077337:Vorinostat
chemical_list: D056572:Histone Deacetylase Inhibitors; D006877:Hydroxamic Acids; D000077337:Vorinostat